Pharmafile Logo

News and Press Releases

T-CURX Announces $20M Series A First Closing Led by BiomedVC to Fund Pipeline of Clinical-Stage CAR-T Programs and Advance Proprietary Non-Viral In Vivo CAR-T Platform

17 December 2025 -- Würzburg, Germany -- T-CURX GmbH (T-CURX) today announces the first closing of a $20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 17, 2025

T-CURX
info@t-curx.com
Innovations- und Gründerzentrum Würzburg Friedrich-Bergius-Ring 15 97076 Würzburg Deutschland/Germany

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

Enables in vivo delivery of LEU011 harnessing the VivoCell Platform 15 December 2025 -- London, UK and Illinois, US -- Leucid Bio, a privately-held biotechnology company developing innovative Chimeric Antigen Receptor...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025

Leucid Bio
info@leucid.com
3rd Floor, Bermondsey Wing Guy's Hospital London SE1 9RT

Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer

Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...

Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025

GSK
980 Great West Rd, London TW8 9GS

Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates

Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025

Commit Biologics
info@commitbio.com
Universitetsbyen 83 8000 Aarhus C, Denmark

Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma

Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8 HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 6, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Ryvu Therapeutics Announces Three Abstracts on Romaciclib (RVU120) and One Abstract on Dapolsertib (MEN1703) at the 2025 ASH Annual Meeting

Romaciclib continues to show efficacy in AML: Data from the Phase II RIVER-81 trial suggest that romaciclib restores sensitivity to venetoclax in resistant AML, inducing complete remissions with a favorable safety profile Clinical activity in myelofibrosis (MF): Interim results from the Phase II POTAMI-61 study indicate clinically meaningful spleen volume...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 3, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

3 November 2025 -- Massachusetts, US -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced three presentations of new preclinical data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 3, 2025

Tessera Therapeutics
101 South St, Somerville, MA 02143, United States

Ryvu Therapeutics Presents RVU305 (PRMT5i) and ONCO Prime Platform Data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates strong and selective antitumor efficacy in MTAP-deleted glioblastoma models, with confirmed brain exposure and a favorable safety profile supporting IND/CTA-enabling studies...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 23, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Iksuda to present IKS014 Phase 1 data at ESMO

14 October 2025 -- Newcastle, UK -- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Clinigen to Acquire SSI Strategy, Charting a Seamless Path from Clinical Strategy to Global Commercialisation for Biotech Innovators

29 September 2025 -- London, UK -- Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, today announced it has entered into a definitive agreement to...

Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: September 29, 2025

Clinigen
25 Bedford Square Bloomsbury London WC1B 3HH

Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure

7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025

Heartbeat.Bio
office@heartbeat.bio
Vienna Biocenter 6 Dr. Bohr-Gasse 7 A-1030 Vienna Austria

Iksuda Therapeutics receives FDA IND clearance for IKS014

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers

Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study,...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025

Kite Pharma
2400 Broadway Santa Monica, CA 90404